Today was another macro day in that the macro environment had a lot more to do with price movements than fundamentals. That being said, bios seemed to be strong in.
While the market got some intraday whipsaw action, it seemed generally good and biotechs did well- early. We had a late day sell-off with biotechs seeming to do better than.
Outside of a not completely unexpected merger, it was a relatively quite start to the week. As has been par for the course, ASCO oncology stocks tended to be weak.
A lot of movers today and most were deep in the red. A lot of the moves were ASCO stocks selling off after the abstracts were released last night but.